Neurocrine names Roberts CMO. Neurocrine Biosciences stock sits 23.07 percent below its high

Published on 10/05/2026 at 09:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 959 million in second-quarter 2026, up 39.50 percent. Neurocrine Biosciences stock is EUR 128.00 on October 5, 2026, up 0.59 percent.

NBIX, US64125C1099, Illustration mit AI erstellt.

Neurocrine Biosciences (ISIN US64125C1099) was trading at EUR 128.00 at Lang & Schwarz on October 5, 2026 at 8:58 a.m. CEST, up 0.59 percent versus the prior close of EUR 127.25. According to StockTitan on September 28, 2026, Neurocrine appointed Eiry W. Roberts, M.D., as chief medical officer.

Roberts takes the medical role

Roberts succeeded Sanjay Keswani, M.D., whose service ended on September 25, 2026 by mutual agreement, according to StockTitan. The filing also described a USD 825,000 annual base salary and equity grants with stated target values of USD 625,000 in stock options, USD 250,000 in restricted stock units and USD 375,000 in performance units.

Second-quarter growth resets the base

Neurocrine reported USD 959.0 million of revenue in the second quarter of 2026, compared with USD 689.0 million in the prior-year quarter, a 39.50 percent increase, according to MarketBeat. Non-GAAP earnings per share were USD 2.85 against a USD 1.65 consensus estimate, while GAAP net income was USD 144.0 million in the quarter, according to StockTitan.

The company also raised 2026 INGREZZA net sales guidance to USD 2.825 billion to USD 2.875 billion. INGREZZA generated USD 716.0 million in second-quarter 2026 net product sales, while CRENESSITY contributed USD 184.0 million, according to StockTitan.

The stock remains below its high

Neurocrine had a USD 14.4 billion market capitalization on October 2, 2026. Its Nasdaq price was USD 143.18 on that date, 23.07 percent below the USD 186.12 52-week high and above the USD 122.14 low. The figures show that the September decline left the stock well below its yearly peak even as quarterly revenue accelerated.

Investing.com reported on September 29, 2026 that UBS lowered its price target from USD 231 to USD 214 while maintaining a Buy rating. The report cited additional VYKAT safety findings, competition for CRENESSITY and pricing headwinds for INGREZZA as factors behind the lower target.

Price and company profile

At Lang & Schwarz, Neurocrine was trading at EUR 128.00 on October 5, 2026 at 8:58 a.m. CEST, plus 0.59 percent versus the EUR 127.25 prior close. The pre-market quote gives German investors a current euro reference while the Nasdaq figures provide the separate U.S. market context.